Novo Nordisk has expanded its artificial-intelligence strategy through a collaboration with Anthropic that will test Claude Science in pharmaceutical R&D, adding another AI partner as the drugmaker seeks faster research productivity amid intensifying competitive pressure.
Roche has secured FDA Priority Review for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease after Phase 3 data showed a 68% reduction in relapse risk versus placebo.
Enhertu reduced the risk of progression or death by 37% against pembrolizumab plus chemotherapy in first-line HER2-mutant metastatic non-small cell lung cancer, potentially opening another earlier-treatment market for AstraZeneca and Daiichi Sankyo.
Johnson & Johnson’s Rybrevant combination produced a median overall survival of 34.3 months in first-line EGFR exon 20 insertion-positive lung cancer, although the protocol-specified comparison did not reach statistical significance after extensive crossover from chemotherapy.
Cogent now has three bezuclastinib NDAs under FDA review, with GIST and non-advanced mastocytosis decisions due before year-end.
Ocular Therapeutix keeps its AXPAXLI wet AMD NDA on track for Q4 after a positive FDA meeting, but OCUL still falls nearly 5%.
CNTB falls 32% after rademikibart misses its asthma primary endpoint despite a 66% treatment-failure reduction and significant FEV1 gain.
SELLAS investors await event-driven Phase 3 AML results while SLS009 heads to AACR with preclinical pancreatic cancer combination data.
Biohaven’s opakalim program faces an FDA partial hold over a rodent metabolite, while a fully enrolled pivotal epilepsy study remains on track.
Iovance approaches new lung cancer data as Amtagvi revenue hits $91 million and IOVA trades near a 52-week high after a major 2026 rally.